Clinical Trial Update: Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. [Phase 2]

View source ↗

Summary

Phase II study of front-line ponatinib in adults with Philadelphia-positive/BCR-ABL-positive acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bcr-abl Positive Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Ponatinib (ponatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Philadelphia Positive, BCR-ABL Positive | Phase 2 | Status: COMPLETED